[Comment] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer

Over the past decade, targeted radionuclide therapy has progressed substantially, especially for the treatment of neuroendocrine tumours. The frequent overexpression of prostate-specific membrane antigen (PSMA) in prostate cancers opened the way for the development of tracers for diagnostic purposes and for therapeutic applications, thereby offering a more precise and personalised approach for the treatment of castration-resistant tumours.1